Key result
The efficacy of statin therapy in preventing major vascular events and all-cause mortality in the elderly remains uncertain due to inadequate representation in previous trials.
Why the study?
Does statin therapy prevent major vascular events and all-cause mortality in elderly patients over 70?
Does statin therapy prevent major vascular events and all-cause mortality in elderly patients over 70?
The efficacy and safety of statin therapy in patients over 70 remain uncertain, highlighting the need for real-world trials in this demographic.
Statin decisions in patients over 70 should remain individualized; leaves open the need for dedicated elderly outcome trials.
PURPOSE OF REVIEW: A strong potential exists for greater promotion of statin therapy among the over-70 age group on the basis of their high absolute cardiovascular risk. However, the evidence for this approach is currently unclear. RECENT FINDINGS: Meta-analysis of trials highlights the uncertainty about the efficacy of statins in the prevention of major vascular events and all-cause mortality in the elderly. This stems from inadequate numbers of participants from this age group included in previous randomized clinical trials. Adverse effects of statins are likely to be greater in the elderly, but their frequency is uncertain and their contribution to frailty and loss of independence in the elderly has been little studied. SUMMARY: Real world trials examining the impact of statin therapy in the elderly are now called for.
No takes yet. Share an insight, caveat, or question.
Zoungas et al. (2014) conducted a review in Cardiovascular risk. Statin therapy was evaluated on Major vascular events and all-cause mortality. The efficacy of statin therapy in preventing major vascular events and all-cause mortality in the elderly remains uncertain due to inadequate representation in previous trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: